Here is the design of a clinical trial:

Official Title: Safety and Efficacy of Glibenclamide Combined With Rt-PA in Treating Acute Ischemic Stroke: a Prospective, Randomized, Double-blind, Placebo-control, Multi-center Study

Included conditions:
- Acute Stroke

Study Armgroups:
- {'label': 'Glibenclamide', 'type': 'ACTIVE_COMPARATOR', 'description': 'Glibenclamide Tablets', 'interventionNames': ['Drug: Glibenclamide']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Placebo for Glibenclamide', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Glibenclamide', 'description': 'Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.', 'armGroupLabels': ['Glibenclamide']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': 'Functional outcome: The proportion of mordified Rankin Scale of 0 to 2 points', 'description': 'The proportion of mordified Rankin Scale of 0 to 2 points at 90 days', 'timeFrame': '90 days after the stroke onset'}

Please estimate the sample size based on the assumption: 
A two-sided significance level of 0.05, a power of 80%, the O'Brien-Fleming alpha spending function, and a dropout rate of less than 10% are assumed.
Sample size estimation
        The sample size calculation was based on previous findings, and the proportion of patient with a mRS of 0â2 at 90âdays of 41% was estimated for the placebo group, and of 58% was assumed for the glibenclamide-treated group [11]. When half of the planned subjects finish their 90-day follow up an interim analysis will be conducted and the OâBrien - Fleming method will be used to control the type I error. Using nQuery + nTerim 4.0 (Statistical Solutions Ltd., Farmerâs Cross, Cork, Ireland) with a 2-sided Ï2 test, a two-sided significance level of 0.05, a power of 80%, the OâBrien - Fleming alpha spending function and a dropout rateâ<â10%, 153 patients are required in each group, for a total sample size of 306.